| Patient | Johnny Cash |
|---|---|
| Date of birth | 1955-02-26 |
| Identifiers | MRN HR-ML004-SYN; SSN (made up) 000-04-8125 |
| Document date | 2026-02-27 |
| Author | Gideon Hale, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Primary care new-patient visit for diabetes, lightheadedness on standing, and glaucoma follow-up [S]
This fictional modern episode addresses the presenting concerns below. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
1 later historical claim is omitted because it describes events after the index age. See the teaching note.
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1957 | Amphetamine use beginning in 1957, with barbiturates in the 1960s; addiction lasting about a decade | D (CLM-0004) |
| 1983 | Hospitalized in 1983 with internal bleeding, followed by treatment at the Betty Ford Clinic | D (CLM-0005) |
| October 1997 | Diagnosed with Shy-Drager syndrome in October 1997; he said in 2000 that it was a misdiagnosis, and autonomic neuropathy was later identified | D (CLM-0006, CLM-0007) |
| February 2001 | Pneumonia treated at Baptist Hospital in Nashville in February 2001, one of several pneumonia admissions | D (CLM-0008) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| brother | Older brother Jack died in a sawmill accident in 1944 | D (CLM-0003) |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 500 mg oral tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with meals | Oral route | 2024-05-06 to 2026-02-27 | completed | S |
| Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals | One tablet by mouth twice daily with meals | Oral route | 2026-02-27 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-02-27 | active | S |
| Latanoprost 0.005% ophthalmic solution, one drop in each eye at bedtime | One drop in each eye at bedtime | Ophthalmic route | 2023-09-11 | active | S |
| Dorzolamide 2% ophthalmic solution, one drop in each eye twice daily | One drop in each eye twice daily | Ophthalmic route | 2026-02-27 | active | S |
Positive for the concerns in the history of present illness. Alert, oriented, and wry; speaks frankly about his past substance use and his faith. Mood euthymic; PHQ-2 negative; Mini-Cog normal. No other systems reported as affected in this synthetic episode. [S]
Alert and engaged. Orthostatic vital signs at intake: 146/80 seated and 112/68 after three minutes standing, heart rate 78 to 82; lightheaded on standing and two falls in six months. Walks with a cane; reduced vibration and monofilament sensation to the ankles in both feet; independent in basic activities of daily living. Low vision from advanced glaucoma: tunnel vision in both eyes and difficulty in dim light; no longer drives. [S]
Vital signs recorded on 2026-02-27; see the Vital Signs section. Mental status: Alert, oriented, and wry; speaks frankly about his past substance use and his faith; Mood euthymic; PHQ-2 negative; Mini-Cog normal. The physical examination is limited to the findings relevant to this synthetic episode. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-27 | Body height | 188 | cm | S |
| 2026-02-27 | Body weight | 96 | kg | S |
| 2026-02-27 | Body mass index (BMI) [Ratio] | 27.2 | kg/m2 | S |
| 2026-02-27 | Systolic blood pressure | 146 | mm[Hg] | S |
| 2026-02-27 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-02-27 | Heart rate | 78 | /min | S |
| 2026-02-27 | Respiratory rate | 16 | /min | S |
| 2026-02-27 | Body temperature | 36.7 | Cel | S |
| 2026-02-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 95 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-27 | Hemoglobin A1c/Hemoglobin.total in Blood | 8.6 | % | <=5.6% | High | S |
| 2026-02-27 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-27 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-27 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-02-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 74 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-27 | Glucose [Mass/volume] in Serum or Plasma | 186 | mg/dL | 70-99 mg/dL | High | S |
| 2026-02-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 128 | mg/dL | <=99 mg/dL | High | S |
| 2026-02-27 | Albumin/Creatinine [Mass Ratio] in Urine | 18 | mg/g | <=30 mg/g | Normal | S |
| 2026-02-27 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 7-56 U/L | Normal | S |
| 2026-02-27 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 22 | U/L | 10-40 U/L | Normal | S |
| 2026-02-27 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 286 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-02-27 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.45-4.5 mIU/L | Normal | S |
| 2026-02-27 | Hemoglobin [Mass/volume] in Blood | 13.8 | g/dL | 13.2-16.6 g/dL | Normal | S |
| 2026-02-27 | Right eye Intraocular pressure | 22 | mm[Hg] | 10-21 mmHg | High | S |
| 2026-02-27 | Left eye Intraocular pressure | 24 | mm[Hg] | 10-21 mmHg | High | S |
| 2026-02-27 | Right retina Retinal nerve fiber layer.mean thickness by OCT | 61 | um | 80-120 um | Low | S |
| 2026-02-27 | Left retina Retinal nerve fiber layer.mean thickness by OCT | 57 | um | 80-120 um | Low | S |
| 2026-02-27 | Visual acuity best corrected Right eye by ETDRS eye chart | 68 | {letters} | >=80 | Low | S |
| 2026-02-27 | Visual acuity best corrected Left eye by ETDRS eye chart | 63 | {letters} | >=80 | Low | S |
| 2026-02-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S | ||
| 2026-02-27 | Total score [Mini-Cog] | 5 | {score} | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes mellitus with diabetic autonomic neuropathy; HbA1c above the individualized goal at intake | active | confirmed | E11.43 | S — Synthetic modern diagnosis linked to the publicly reported diabetes and autonomic neuropathy. |
| Neurogenic orthostatic hypotension from diabetic autonomic neuropathy | active | confirmed | I95.1 | S — Synthetic finding; explains the autonomic symptoms once labeled Shy-Drager syndrome. |
| Diabetic distal symmetric polyneuropathy with loss of protective sensation in both feet | active | confirmed | E11.42 | S — Synthetic finding linked to his description of numb lower extremities. |
| Primary open-angle glaucoma, both eyes, severe stage | active | confirmed | H40.1133 | S — Synthetic modern diagnosis; the type and stage are not documented historically. |
| Mild nonproliferative diabetic retinopathy without macular edema, both eyes | active | confirmed | E11.3293 | S — Synthetic finding from the dilated eye examination. |
| Hyperlipidemia | active | confirmed | E78.5 | S — Synthetic finding from the baseline LDL cholesterol. |
| History of recurrent pneumonia | active | confirmed | Z87.01 | S — Synthetic modern coding of the documented recurrent pneumonia; supports pneumococcal vaccination. |